The Effect of Irisin on Proliferation, Apoptosis, and Expression of Metastasis Markers in Prostate Cancer Cell Lines

Sadr, Atiye Saeedi; Ehteram, Hassan; Hosseini, Elahe Seyed; Zarei, Marziyeh Alizadeh; Bafrani, Hassan Alizadeh; Kashani, Hamed Haddad

doi:10.1007/s40487-022-00194-4

Cited by 9 publications

(6 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irisin is an adipomyokine that is involved in the regulation of metabol is an exercise-induced polypeptide secreted by skeletal muscle. Irisin is at between cancer and PD, being able to ameliorate the course of both diseas confirmed that irisin inhibits in vitro proliferation, migration, and invasion ences inflammatory processes, including cancer, and decreases the expres markers [19,20].…”

Section: Irisin Is At the Crossroads Between Cancer And Pdmentioning

confidence: 68%

Association between Parkinson’s Disease and Cancer: New Findings and Possible Mediators

Surguchov,

Surguchev

2024

IJMS

View full text Add to dashboard Cite

Epidemiological evidence points to an inverse association between Parkinson’s disease (PD) and almost all cancers except melanoma, for which this association is positive. The results of multiple studies have demonstrated that patients with PD are at reduced risk for the majority of neoplasms. Several potential biological explanations exist for the inverse relationship between cancer and PD. Recent results identified several PD-associated proteins and factors mediating cancer development and cancer-associated factors affecting PD. Accumulating data point to the role of genetic traits, members of the synuclein family, neurotrophic factors, the ubiquitin–proteasome system, circulating melatonin, and transcription factors as mediators. Here, we present recent data about shared pathogenetic factors and mediators that might be involved in the association between these two diseases. We discuss how these factors, individually or in combination, may be involved in pathology, serve as links between PD and cancer, and affect the prevalence of these disorders. Identification of these factors and investigation of their mechanisms of action would lead to the discovery of new targets for the treatment of both diseases.

show abstract

Section: Irisin Is At the Crossroads Between Cancer And Pdmentioning

confidence: 68%

Association between Parkinson’s Disease and Cancer: New Findings and Possible Mediators

Surguchov,

Surguchev

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Literature evidence has shown that irisin can modulate the proliferation of many cancer cells. In particular, in vitro studies demonstrated that irisin inhibited the number of malignant breast, 24 prostate, 26 lung, 27 ovarian 25 and pancreatic cancer cells 28 as well as osteosarcoma cells, 23 but the effects on myeloma cells have not been studied up to now. Sabol et al recently demonstrated that Notch 3 signaling, activated through homotypic plasma cell interaction, contributes to their growth by upregulating Cyclin D1.…”

Section: Discussionmentioning

confidence: 99%

Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma

Zerlotin,

Oranger,

Pignataro

et al. 2024

JBMR Plus

View full text Add to dashboard Cite

Bone disease (BD) associated with multiple myeloma (MM) is characterized by osteolytic lesions and pathological fractures, which remain a therapeutic priority despite new drugs improving MM patient survival. Antiresorptive molecules represent the main option for the treatment of MMBD whereas osteoanabolic molecules are under investigation. Among these latter, we here focused on the myokine irisin, able to enhance bone mass in healthy mice, prevent bone loss in osteoporotic mouse models, and accelerate fracture healing in mice. Therefore, we investigated irisin effect on MMBD in a mouse model of MM induced by intratibial injection of myeloma cells followed by weekly administration of 100 μg/Kg of recombinant-irisin for 5 weeks. By micro-Ct analysis, we demonstrated that irisin improves MM-induced trabecular bone damage by partially preventing the reduction of femur Trabecular Bone Volume/Total Volume (p = 0.0028), Trabecular Number (p = 0.0076), and Trabecular Fractal Dimension (p = 0.0044), and increasing Trabecular Separation (p = 0.0003) in MM mice. In cortical bone, irisin downregulates the expression of Sclerostin, the bone formation inhibitor, and RankL, the pro-osteoclastogenic molecule, and in bone marrow (BM) upregulates Opg, the anti-osteoclastogenic cytokine. We found that in the BM tibia of irisin-treated MM mice, the percentage of MM cells displays a reduction trend, while in the femur it decreases significantly. This is in line with the in vitro reduction of myeloma cell viability after 48 hours of irisin stimulation at both 200 and 500 ng/ml and after 72 hours already at 100 ng/ml rec-irisin. These results could be due to irisin ability to downregulate the expression of Notch 3, important for cell-to-cell communication in the tumor niche, and Cyclin D1, regulator of cell cycle progression, supporting an inhibitory effect of irisin in MM cell proliferation. Overall, our findings suggest that irisin could be a new promising strategy to counteract MMBD and tumor burden in one shot.

show abstract

“…A number of tumor samples were excluded from the study owing to inappropriate paraffin blocks, low-quality staining, and unavailable data. Also, the small-sized specimens prepared by biopsy that were inadequate for performing histopathological examinations were excluded [ 33 – 35 ].…”

Section: Methodsmentioning

confidence: 99%

Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction Today, colon cancer is one of the most common types of gastrointestinal cancer worldwide. CD133 as a known cancer stem cell marker has been found effective in cell proliferation and differentiation in various cancers, including colon cancer. We aimed to investigate the relationship between CD133 expression in colon cancer with prognostic factors and survival rate of patients with colon cancer by immunohistochemistry. Methods Formalin-fixed paraffin-embedded (FFPE) tissue was taken from patients with colon cancer. Histopathology examination was done using hematoxylin and eosin staining. Immunohistochemistry was performed to determine CD133 expression. Association between CD133 expression and clinicopathological profile was then assessed. Results There was a statistically significant association between CD133 protein expression and sex , cancer stage, and lymphatic invasion ( p = 0.044, p = 0.131, and p = 0.002, respectively). However, no significant correlation was identified between CD133 expression and other factors, including age of patients with colorectal cancer (CRC) ( p = 0.267), tumor location ( p = 0.494), tumor differentiation grade ( p = 0.263), neural tissue invasion, and 5-year survival ( p = 0.054). Conclusion CD133 is a useful predictive or prognostic biomarker for CRC in clinical assessment and may serve as a potential therapeutic target for CRC.

show abstract

The Effect of Irisin on Proliferation, Apoptosis, and Expression of Metastasis Markers in Prostate Cancer Cell Lines

Cited by 9 publications

References 57 publications

Association between Parkinson’s Disease and Cancer: New Findings and Possible Mediators

Association between Parkinson’s Disease and Cancer: New Findings and Possible Mediators

Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma

Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer

Contact Info

Product

Resources

About